Diabetes-related end-stage renal disease in Austria 1965-2013

Nephrology Dialysis Transplantation

Volumn 30, Issue 11, 2015, Pages 1920-1927

  Prischl, Friedrich C ^a   Auinger, Martin ^b   Säemann, Marcus ^c   Mayer, Gert ^d   Rosenkranz, Alexander R ^e   Wallner, Manfred ^a   Kramar, Reinhard ^f  

^a Klinikum Wels Grieskirchen GmbH   (Austria)

^b Neurological Center Rosenhuegel   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f Rohr Kremstal   (Austria)

Author keywords

Diabetic kidney disease; Diabetic nephropathy; Endstage renal disease; Incidence; Survival probability

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRIA; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; SEX DIFFERENCE; SURVIVAL PREDICTION; SURVIVAL TIME; COMPLICATION; DIABETIC NEPHROPATHIES; EPIDEMIOLOGY; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; REGISTER; TIME FACTOR;

ADULT; AGED; AUSTRIA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RENAL DIALYSIS; TIME FACTORS;

EID: 84948425870     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv113     Document Type: Article

References (36)

1. Wilson JL, Root HF, Marble A. Diabetic nephropathy - A clinical syndrome. N Engl J Med 1951; 245: 513-517
2. Kimmelstiel P,Wilson C. Intercapillary lesions in glomeruli of kidney.AmJ Pathol 1936; 12: 83-98
3. Polonsky KS. The past 200 years in diabetes. N Engl J Med 2012; 367: 1332-1340
4. Klimont J, Kytir J, Leitner B. Statistik Austria. Austrian Health Survey 2006/ 2007 (Österreichische Gesundheitsbefragung 2006/2007). On behalf of the Austrian Ministry of Health: p20 and p70-71. http://www.statistik.at/web-de/statistiken/gesundheit/index.html (4 December 2014, date last accessed)
5. GreggEW, Cheng YJ, Saydah S et al. Trends in death rates among US adults with and without diabetes between 1997 and 2006. Diabetes Care 2012; 35: 1252-1257
6. Gregg EW, Li Y,Wang J et al. Changes in Diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014; 370: 1514-1523
7. deBoer IH, Rue TC, Hall YN et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. J Am Med Assoc 2011; 305: 2532-2539
8. United States Renal Data System. 2013 Atlas of CKD & ESRD, Volume 2 - Atlas ESRD, Chapter 1: Incidence, prevalence, patient characteristics and modalities. http://www.usrds.org/atlas13.aspx (4 December 2014, date last accessed)
9. Kramar R. Austrian Dialysis and Transplantation Registry (OEDTR), Annual Report 2012, Austrian Society of Nephrology. www.nephro.at (14 January 2015, date last accessed)
10. Statistik Austria. Federal bureau of statistics in Austria. Section on health statistics. http://www.statistik.at/web-de/statistiken/bevoelkerungsstand-und-veraenderung/index.html (18 February 2015, date last accessed)
11. Eurostat. http://ec.europa.eu/eurostat/data/database#. Date of extraction: Feb 17 2015 TApbsaf-ya, (Population 1 January by five years age group and sex (demo pjangroup)) (17 February 2015, date last accessed)
12. Chazan BI, Rees SB, Balodimos MC et al. Dialysis in diabetics. A review of 44 patients. J Am Med Assoc 1969; 209: 2026-2030
13. Ghavamian M, Gutch CF, Kopp KF et al. The sad truth about hemodialysis in diabetic nephropathy. J Am Med Assoc 1972; 222: 1386-1389
14. Friedman EA, Friedman AL, Eggers P. End-stage renal disease in diabetic persons: is the pandemic subsiding? Kidney Int 2006; 70: S51-S54
15. Morbidity and Mortality Weekly Report, Centers for Disease Control and Prevention. Atlanta, GA, 2005; 54: 1097-1100
16. Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 2010; 33: 73-77
17. Comas J, Arcos E, Castell C et al. Evolution of the incidence of chronic kidney disease stage 5 requiring renal replacement therapy in the diabetic population of Catalonia. Nephrol Dial Transplant 2013; 28: 1191-1198
18. The ESRD Incidence Study GroupStewart JH, McCredie MR,Williams SM. Divergent trends in the incidence of end-stage renal disease due to type 1 and type 2 diabetes in Europe, Canada and Australia during 1998-2002. Diabet Med 2006; 23: 1364-1369
19. Hill CJ, Fogarty DG. Changing trends in end-stage renal disease due to diabetes in the United Kingdom. J Renal Care 2012; 38 (Suppl 1): 12-22
20. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal data System. J Am Soc Nephrol 2007; 18: 2644-2648
21. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials. Brit Med J 2011; 343: d4169. doi: 10.1136/bmj. d4169
22. Coca SG, Ismail-Beigi F, Haq N et al. Role of intensive glucose control in development of renal endpoints in type 2 diabetes mellitus. Arch Intern Med 2012; 172: 761-769
23. Shurraw S, Hemmelgarn B, LinMet al. for the Alberta Kidney Disease Network. Association between glycemic control and adverse outcome in people with diabetes mellitus and chronic kidney disease. Arch Intern Med 2011; 171: 1920-1927
24. Holman RR, Paul SK, BethelA et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576
25. Vejakama P, Thakkinstian A, Lertrattananon D et al. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012; 55: 566-578
26. Adarkwah CC, Gandjour A, Akkerman M et al. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in the Netherlands - A Markov model. PLoS ONE 2011; 6: e26139
27. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type 1 and type 2 diabetes mellitus. Nephrol Dial Transplant 1994; 9: 1097-1102
28. Thomas MC, Rosengard-Bärlund M, Mills V et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 2006; 29: 317-322
29. Fellström BC, Jardine AG, Schmieder RE et al. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
30. Wanner C, Krane V, MarzWet al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
31. Howden EJ, Leano R, PetcheyWet al. Effect of exercise and lifestyle intervention on cardiovascular function in CKD. Clin JAmSoc Nephrol 2013; 8: 1494-1501
32. Huang X, Jimenez-Moleon JJ, Lindholm B et al. Mediterranean diet, kidney function, and mortality in men with CKD. Clin J Am Soc Nephrol 2013; 8: 1548-1555
33. Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. Kidney Int 2011; 80: 516-523
34. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591
35. Villar E, Chang SH, McDonald SP. Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991-2005). Diabetes Care 2007; 30: 3070-3076
36. Schroijen MA, van de Luijtgaarden MWM, Noordzij M et al. Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition. Diabetologia 2013; 56: 1949-1957